Lanean...
Optimising infliximab induction dosing for patients with ulcerative colitis
AIMS: The therapeutic failure of infliximab therapy in patients with ulcerative colitis remains a challenge even 2 decades after its approval. Therapeutic drug monitoring (TDM) has shown value during maintenance therapy, but induction therapy has still not been explored. Patients may be primary nonr...
Gorde:
| Argitaratua izan da: | Br J Clin Pharmacol |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6422726/ https://ncbi.nlm.nih.gov/pubmed/30634202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13859 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|